[go: up one dir, main page]

NO20092633L - Ernaeringstilskuddsammensetning for behandling av okulare sykdommer - Google Patents

Ernaeringstilskuddsammensetning for behandling av okulare sykdommer

Info

Publication number
NO20092633L
NO20092633L NO20092633A NO20092633A NO20092633L NO 20092633 L NO20092633 L NO 20092633L NO 20092633 A NO20092633 A NO 20092633A NO 20092633 A NO20092633 A NO 20092633A NO 20092633 L NO20092633 L NO 20092633L
Authority
NO
Norway
Prior art keywords
supplement composition
treatment
nutritional supplement
ocular diseases
spot degeneration
Prior art date
Application number
NO20092633A
Other languages
English (en)
Inventor
Georg Ludwig Kis
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=38024441&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NO20092633(L) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of NO20092633L publication Critical patent/NO20092633L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A61K31/07—Retinol compounds, e.g. vitamin A
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A61K31/202—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids having three or more double bonds, e.g. linolenic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/28—Compounds containing heavy metals
    • A61K31/30—Copper compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/28—Compounds containing heavy metals
    • A61K31/315—Zinc compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
    • A61K31/355—Tocopherols, e.g. vitamin E
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A61K31/375—Ascorbic acid, i.e. vitamin C; Salts thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/34—Copper; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/10—Ophthalmic agents for accommodation disorders, e.g. myopia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Ophthalmology & Optometry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Urology & Nephrology (AREA)
  • Inorganic Chemistry (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Plant Substances (AREA)

Abstract

Den foreliggende oppfinnelsen vedrører en antioksidant- og luteinsupplementssammensetning, som blant annet reduserer skarpsynstap ved å redusere risikoen for å utvikle senstadier eller fremskreden aldersrelatert flekkdegenerasjon hos folk med tidlig aldersrelatert flekkdegenerasjon.
NO20092633A 2006-12-15 2009-07-10 Ernaeringstilskuddsammensetning for behandling av okulare sykdommer NO20092633L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP06126261A EP1932521A1 (en) 2006-12-15 2006-12-15 Nutritional supplement composition for treatment of ocular diseases
PCT/EP2007/063908 WO2008071775A1 (en) 2006-12-15 2007-12-13 Nutritional supplement composition for treatment of ocular diseases

Publications (1)

Publication Number Publication Date
NO20092633L true NO20092633L (no) 2009-07-10

Family

ID=38024441

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20092633A NO20092633L (no) 2006-12-15 2009-07-10 Ernaeringstilskuddsammensetning for behandling av okulare sykdommer

Country Status (22)

Country Link
US (1) US20100028459A1 (no)
EP (2) EP1932521A1 (no)
JP (1) JP2010513248A (no)
KR (1) KR20090089473A (no)
CN (1) CN101557807A (no)
AR (1) AR064332A1 (no)
AU (1) AU2007331432A1 (no)
BR (1) BRPI0720046A2 (no)
CA (1) CA2672013A1 (no)
CL (1) CL2007003630A1 (no)
CO (1) CO6220929A2 (no)
EC (1) ECSP099516A (no)
GT (1) GT200900161A (no)
MA (1) MA30994B1 (no)
MX (1) MX2009006306A (no)
NO (1) NO20092633L (no)
PE (1) PE20081580A1 (no)
RU (1) RU2009126735A (no)
TN (1) TN2009000241A1 (no)
TW (1) TW200843725A (no)
WO (1) WO2008071775A1 (no)
ZA (1) ZA200903862B (no)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8389504B2 (en) * 2008-05-08 2013-03-05 Mead Johnson Nutrition Company Prenatal dietary supplement
US20100159029A1 (en) * 2008-12-23 2010-06-24 Alcon Research, Ltd. Composition and nutritional supplements for improving ocular health and reducing ocular inflammatory response
US20110237548A1 (en) * 2009-07-23 2011-09-29 U.S. Nutraceuticals, Llc D/B/A Valensa International Synergistic composition and method of retarding and ameliorating photo induced retinal damage and cataracts while ameliorating dry eye syndrome using omega choline
US20110021465A1 (en) * 2009-07-23 2011-01-27 U.S. Nutraceuticals, Llc D/B/A Valensa International Synergistic composition and method of retarding and ameliorating photo induced retinal damage and cataracts while ameliorating dry eye syndrome
US20130011469A1 (en) 2009-07-23 2013-01-10 U.S. Nutraceuticals, Llc D/B/A Valensa International Krill oil and carotenoid composition, associated method and delivery system
US20130295171A1 (en) 2009-07-23 2013-11-07 U.S NUTRACEUTICALS, LLC d/b/a Valensa International Krill oil and reacted astaxanthin composition and associated method
ES2832734T3 (es) * 2011-07-07 2021-06-11 Howard Foundation Holdings Ltd Mejoras en el rendimiento visual o relacionadas con este
US10709680B2 (en) 2011-07-18 2020-07-14 Physicians Recommended Nutriceuticals, Llc Methods for treating dry eye
US9381183B2 (en) 2012-07-18 2016-07-05 Physicians Recommended Nutriceuticals, Llc Methods for improving the quality of the meibum composition of meibomian glands
US20210121430A1 (en) 2011-07-18 2021-04-29 Prn Physician Recommended Nutriceuticals, Llc Omega-3 fatty acid supplementation for use in treating dry eye
US9115078B2 (en) 2011-07-18 2015-08-25 Physicians Recommended Nutriceuticals, Llc Compositions for improving the quality of the meibum composition of inflamed or dysfunctional meibomian glands
CA2845868C (en) * 2011-09-12 2018-11-06 Tassos GEORGIOU Use of epa and dha in treating occular disorder
CN102538980A (zh) * 2012-01-12 2012-07-04 杭州美盛红外光电技术有限公司 热像装置和热像拍摄方法
JP2016185939A (ja) * 2015-03-27 2016-10-27 ロート製薬株式会社 経口組成物
JP2016190829A (ja) * 2015-03-31 2016-11-10 ウィルファーム株式会社 活性型ｄｈａを含む製剤、強化食品、サプリメント並びに化粧品
JP6056114B2 (ja) * 2015-05-30 2017-01-11 富田製薬株式会社 油状物質含有粉末組成物
CN108208804A (zh) * 2018-01-05 2018-06-29 美博迪尔（北京）生物科技有限公司 一种缓解眼睛干涩、抵御蓝光损伤及保护眼底的组合物及其制备方法
CN108096288A (zh) * 2018-01-16 2018-06-01 南京圣诺生物科技实业有限公司 护眼片及其制备方法和应用
WO2020109192A1 (en) * 2018-11-27 2020-06-04 Novaliq Gmbh Semifluorinated alkane compositions comprising omega-3 fatty acid ethyl esters
BR112022018122A2 (pt) * 2020-03-11 2022-11-08 Bausch & Lomb Ireland Ltd Composições e métodos para saúde ocular compreendendo ácidos gordos de cadeia muito longa
WO2025151943A1 (pt) * 2024-01-18 2025-07-24 Moro Peres Nemecio Suplemento alimentar particularmente indicado para combate da degeneração macular, cápsula compreendendo o dito suplemento e uso do mesmo

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003003981A2 (en) * 2001-07-05 2003-01-16 Vital Basics, Inc. Compositions for improving mental performance
US6649195B1 (en) * 2002-07-11 2003-11-18 Vitacost.Com, Inc. Eyesight enhanced maintenance composition
US20050112210A1 (en) * 2003-09-12 2005-05-26 Terry Grossman Eye nutritional supplement
US7887847B2 (en) * 2004-05-08 2011-02-15 Paul Jr Edward L Nutritional supplement for treatment of ocular diseases
DE202005012984U1 (de) * 2005-08-17 2005-11-24 W & B Pharmamarken Gmbh Arzneimittel- und Nahrungsergänzungsmittelkombinationen zur Behandlung von Augenerkrankungen
WO2007076416A2 (en) * 2005-12-20 2007-07-05 Alcon Research, Ltd. Composition and methods for inhibiting the progression macular degeneration and promoting healthy vision

Also Published As

Publication number Publication date
CN101557807A (zh) 2009-10-14
EP2094252A1 (en) 2009-09-02
EP1932521A1 (en) 2008-06-18
ECSP099516A (es) 2009-08-28
TW200843725A (en) 2008-11-16
KR20090089473A (ko) 2009-08-21
CA2672013A1 (en) 2008-06-19
US20100028459A1 (en) 2010-02-04
GT200900161A (es) 2009-11-30
ZA200903862B (en) 2010-05-26
JP2010513248A (ja) 2010-04-30
BRPI0720046A2 (pt) 2013-12-24
TN2009000241A1 (en) 2010-10-18
MX2009006306A (es) 2009-06-23
CL2007003630A1 (es) 2008-08-08
AR064332A1 (es) 2009-04-01
PE20081580A1 (es) 2009-01-01
CO6220929A2 (es) 2010-11-19
MA30994B1 (fr) 2009-12-01
WO2008071775A1 (en) 2008-06-19
AU2007331432A1 (en) 2008-06-19
RU2009126735A (ru) 2011-01-20

Similar Documents

Publication Publication Date Title
NO20092633L (no) Ernaeringstilskuddsammensetning for behandling av okulare sykdommer
WO2010130832A3 (en) Amino acid sequences directed against dickkopf-1 and polypeptides comprising the same for the treatment of diseases and disorders associated with bone loss and/or osteolytic lesions
WO2009126688A8 (en) Novel compositions and methods for the treatment of immune related diseases
WO2008002571A3 (en) Human protein tyrosine phosphatase inhibitors and methods of use
EP2592073A3 (en) Human protein tyrosine phosphatase inhibitors and their use
WO2008002569A3 (en) Human protein tyrosine phosphatase inhibitors and methods of use
WO2010043415A8 (en) Whey protein compositions, methods and uses
WO2008042231A3 (en) Compositions and methods for evaluating and treating heart failure
WO2007127273A3 (en) Methods and compositions for altering cell function
WO2010130830A3 (en) Anti-sclerostin vhh and their use for treating bone diseases
WO2007114945A3 (en) Compositions and methods for enhancing the antioxidant status of animals
WO2007092622A3 (en) Compositions and methods for treating bone
BRPI0507593A (pt) composições contendo cis-isÈmeros de um composto carotenóide e processo
WO2007081729A3 (en) Treatment modalities for autoimmune diseases
WO2010062863A3 (en) Compositions containing satiogens and methods of use
BR112014033102A2 (pt) produto para uso no tratamento profilático ou terapêutico de uma emoção negativa ou comportamento introvertido
JO3358B1 (ar) معالجات حساسية العيون
WO2009085969A3 (en) Compositions and methods to promote implantation and engrafment of stem cells
MX2009006342A (es) Composicion de complemento alimenticio para tratamiento de enfermedades oculares.
WO2008013893A3 (en) Diagnosis and treatment of age related macular degeneration
WO2007098122A3 (en) Methods for the treatment of macular degeneration and related eye conditions
WO2008094825A3 (en) Compositions and methods for maintaining, strengthening, improving or promoting eye health
WO2008016730A3 (en) Compositions and methods for reducing cellular fat
WO2008046865A3 (en) Long-term feed - elderly
ECSP13012799A (es) Uso de composiciones nutricionales que incluyen lactoferrinas para mejorar la resistencia a enfermedades y condiciones

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application